Literature DB >> 26413426

Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?

Tugba Kevser Uzuncakmak1, Sarenur Yilmaz2, Ayse Serap Karadag1, Necmettin Akdeniz1, Ibrahim Akalin2.   

Abstract

Lentiginoses is a clinical feature in which lentigines are remarkably present in large numbers or when they occur in a distinctive distribution on apparently normal skin. This entity may be congenital or acquired and may cover a wide spectrum of diseases ranging from an isolated benign pigmentary disorder to numerous syndromes associated with molecular abnormalities.We present a 59-year-old female patient with multiple lentigines which first emerged 3 y ago concurrently with policytemia vera. The patient had found to be positive for Janus Kinase-2 (JAK-2) mutation. Over activation of the pathway due to JAK-2 V617F mutation is a well-known condition in myeloproliferative diseases but has not been reported in melanocytic disorders. Moreover, several signaling pathways have previously been defined with lentiginosis except JAK-STAT pathway. We want to draw attention to the potential effect of JAK-2 mutation in lentigogenesis with this case report.

Entities:  

Keywords:  Janus-kinase 2; Polycythemia vera; lentiginosis; tyrosine kinase

Year:  2015        PMID: 26413426      PMCID: PMC4583055          DOI: 10.1080/21623996.2015.1071000

Source DB:  PubMed          Journal:  JAKSTAT        ISSN: 2162-3988


  27 in total

1.  3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells.

Authors:  Min-Yi Li; Yan Tian; Li Shen; Ralf Buettner; Hong-Zhi Li; Lucy Liu; Yate-Ching Yuan; Qiang Xiao; Jun Wu; Richard Jove
Journal:  Biochem Pharmacol       Date:  2013-09-07       Impact factor: 5.858

2.  Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept.

Authors:  Lucas Ana Costa; Isabel Belinchón; Isabel Betlloch; María Pérez-Crespo; Javier Mataix
Journal:  Dermatol Online J       Date:  2008-01-15

3.  Bilateral segmental lentiginosis associated with malignant melanomas.

Authors:  B González-Sixto; A Flórez; A Conde Taboada; C De la Torre; M Cruces
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-04-03       Impact factor: 6.166

4.  Amyloids, melanins and oxidative stress in melanomagenesis.

Authors:  Feng Liu-Smith; Carrie Poe; Patrick J Farmer; Frank L Meyskens
Journal:  Exp Dermatol       Date:  2014-11-18       Impact factor: 3.960

Review 5.  The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.

Authors:  Natalia Bezniakow; Monika Gos; Ewa Obersztyn
Journal:  Dev Period Med       Date:  2014 Jul-Sep

6.  Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells.

Authors:  Sangkil Nam; Jun Xie; Angela Perkins; Yuelong Ma; Fan Yang; Jun Wu; Yan Wang; Rong-Zhen Xu; Wendong Huang; David A Horne; Richard Jove
Journal:  Mol Oncol       Date:  2012-06-02       Impact factor: 6.603

7.  RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Authors:  Peter S Winter; Kristopher A Sarosiek; Kevin H Lin; Manja Meggendorfer; Susanne Schnittger; Anthony Letai; Kris C Wood
Journal:  Sci Signal       Date:  2014-12-23       Impact factor: 8.192

8.  Generalized eruptive lentiginosis in a healthy elderly man.

Authors:  Min Sung Kim; Sang Ho Youn; Chan Ho Na; Jong Kyu Kim; Bong Seok Shin
Journal:  Ann Dermatol       Date:  2014-09-26       Impact factor: 1.444

9.  Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.

Authors:  E Gutiérrez-González; A Batalla; D de la Mano
Journal:  Dermatol Online J       Date:  2014-04-16

10.  The thrombotic events in polycythemia vera patients may be related to increased oxidative stress.

Authors:  Ahmet Durmus; Ahmet Mentese; Mustafa Yilmaz; Aysegul Sumer; Ibrahim Akalin; Cevat Topal; Ahmet Alver
Journal:  Med Princ Pract       Date:  2014-03-15       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.